During the past decade, Cancer Center of Kansas-Manhattan conducted 57 clinical trials. In the 10-year time frame, 57 clinical trials started and 55 clinical trials were completed, i.e. on average, 96.5% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 44 clinical trials were completed. i.e. 366.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cancer Center of Kansas-Manhattan" #1 sponsor was "National Cancer Institute (NCI)" with 48 trials, followed by "SWOG Cancer Research Network" with 22 trials sponsored, "Alliance for Clinical Trials in Oncology" with 16 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 9 trials sponsored and "Gynecologic Oncology Group" with 9 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cancer Center of Kansas-Manhattan" #1 collaborator was "National Cancer Institute (NCI)" with 58 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "NRG Oncology" with 5 trials as a collaborator, "Millennium Pharmaceuticals, Inc." with 3 trials as a collaborator and "Bayer" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Cancer Center of Kansas-Manhattan" are "Invasive Breast Carcinoma" (5 trials), "Recurrent Squamous Cell Lung Carcinoma" (5 trials), "Stage IV Cutaneous Melanoma AJCC v6 and v7" (5 trials), "Breast Cancer" (4 trials) and "Recurrent Breast Carcinoma" (4 trials). Many other conditions were trialed in "Cancer Center of Kansas-Manhattan" in a lesser frequency.

Most popular intervention types in "Cancer Center of Kansas-Manhattan" are "Drug" (82 trials), "Other" (71 trials), "Biological" (33 trials), "Procedure" (25 trials) and "Radiation" (9 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (40 trials), "Quality-of-Life Assessment" (25 trials), "Carboplatin" (14 trials), "Paclitaxel" (12 trials) and "Ipilimumab" (11 trials). Other intervention names were less common.

The vast majority of trials in "Cancer Center of Kansas-Manhattan" are 84 trials for "All" genders, 21 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Cancer Center of Kansas-Manhattan". undefined are not yet recruiting, 19 are recruiting, 52 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Cancer Center of Kansas-Manhattan, 1 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Cancer Center of Kansas-Manhattan, 4 "Phase 1" clinical trials were conducted, 48 "Phase 2" clinical trials and 54 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".